Hernia mesh, a surgical patch used to reinforce weakened tissue, pays out based on documented injury severity in a tiered matrix, not a flat rate. Revision or removal surgery, medical bills, lost wages, and strength of product and causation proof set the tier.
Becton Dickinson agreed in October 2024 to resolve roughly 38,000 Bard/Davol suits in federal MDL 2846 and Rhode Island state court. Law.com reported the confidential deal was valued at over $1 billion the October settlement report. That scale makes individual documentation, not the headline total, the driver of what a claimant receives.
Official resources:
- Read the official notice from Ucsf — Use this primary source to verify the official announcement.
- Read the official notice from Drugwatch — Use this primary source to verify the official announcement.
Table of Contents
- How are claims sorted into payout tiers?
- Which injuries and costs raise value?
- Why does mesh brand and failure history matter?
- What records strengthen your payout?
How are claims sorted into payout tiers?
DrugWatch explains court-supervised programs score each claim in a settlement matrix based on documented injury severity the settlement-tier explanation. Revision or mesh-removal surgery scores highest. Lesser injuries with conservative care score lower.
No court published an official average or payment grid. Consumer Notice notes reported $65,000-$80,000 per-claim figures are secondary estimates. Complete operative, revision, and billing records support higher placement.
Which injuries and costs raise value?
Motley Rice describes affected patients as those with Bard polypropylene products such as Ventralight, Ventralex, PerFix Plug and 3DMax who later developed pain, infection, migration, recurrence or organ injury. UCSF, quoting FDA analysis, lists common mesh-repair harms as pain, infection, recurrence, adhesion and bowel obstruction, plus migration and shrinkage.
📨 Get Free Mass Tort Guides Alerts
Free · No spam · Unsubscribe anytime
AboutLawsuits notes past and future medical costs, lost wages, and chronic pain or disability also drive payouts. A second surgery, long-term limits, and ongoing care weigh heavily. Daily-life limits documented by doctors carry more weight than symptoms alone.
Why does mesh brand and failure history matter?
Ethicon withdrew Physiomesh worldwide in 2016 after high recurrence and reoperation rates. Atrium C-QUR Edge received a 2013 Class 2 FDA recall. AboutLawsuits details both actions on its hernia-mesh background page.
A recalled or withdrawn product with a clear failure pattern can strengthen causation. It does not guarantee a higher tier without medical proof. Injury records still decide placement.
What records strengthen your payout?
Strong claims link a specific product to a specific injury. AboutLawsuits identifies product-identification and causation proof as key payout drivers.
Keep the implant label, operative report, and lot number when available. Bellwether verdicts anchor expectations. DrugWatch summarizes a 2023 federal award of $500,000 for Bard PerFix Plug injuries and a 2022 Rhode Island award of $4.8 million against a Bard subsidiary the bellwether case summary.
- Ask the hospital for operative and implant records
- Collect revision, infection-care, and imaging reports
- Save bills, pay stubs, and employer letters for lost wages
- Write a daily log of pain, limits, and follow-up visits
You Might Also Like
- Zantac Lawsuit Update: Is the Cancer Claim Still Open?
- Talcum Powder Lawsuit Eligibility: What Injuries Qualify for a Claim?
- Spinal Cord Stimulator Lawsuit Settlements Explained for MDL Claims